Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Radioligand Binding Assay Services
Perceptive Discovery offers a comprehensive portfolio of radioligand binding assays to support drug development with precision and reliability.
Perceptive Discovery has been a trusted leader in radioligand binding studies for over 15 years. Our global platform integrates radiochemistry services, in vitro and ex vivo pharmacology, homogenate binding and autoradiography techniques to support compound characterization. Our specialized services deliver actionable insights to ensure translational relevance for drug development programs, including those focused on radioligand therapy and theranostics.
Your trusted partner in pharmacology
Radioligand binding assay capabilities
Our services include saturation binding assays for detailed analysis of target expression and ligand affinity, competition assays to evaluate candidate specificity, and cell-based target internalization studies to explore receptor-mediated endocytosis.
With expertise in kinetic analyses and specialized techniques such as Immunoreactive Fraction Assays (IRF) and ex vivo dose occupancy assays, we deliver actionable insights to drive informed decisions and ensure translational relevance. Learn more:
Saturation Binding Assays
In order to de-risk the development of a novel radioligand or to understand the powering of a study associated with altered target expression in disease state, we can perform in vitro autoradiography or homogenate saturation binding assays to measure the target expression (maximum binding signal, BMAX) and ligand affinity (dissociation constant, KD) by traditional pharmacology methods in ethically sourced animal and human tissue.
Competition Binding Assays
Perspective offers competition binding assays performed to determine the relative affinity (Ki) of unlabelled candidates and to determine whether they share the same binding site as a radiolabelled tool compound.
Target Internalisation Assays
Cell-based target internalisation assays can be performed to investigate aspects of receptor-mediated endocytosis and the time course associated with this phenomenon.
Kinetic assays
Kinetic parameters such as the association (Kon) and dissociation (koff) may be determined by using a radiolabelled candidate to establish ligand kinetics.
Other radioligand binding assay approaches used for specific applications include Immunoreactive Fraction Assays (IRF) and ex vivo dose occupancy assays.
Partnering for Imaging Excellence Across Drug Development
Perceptive Discovery is more than just a service provider – we are your trusted imaging partner, supporting drug development from preclinical imaging through translational research and into late-phase clinical trials. Our integrated services are designed to meet your needs at every step. Let’s discuss your next project.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
